| |
| |
| Projects In Knowledge is pleased to present The Advanced Certificate Program: Lung Cancer Management. |
| Featuring the very latest state-of-the-science information about lung cancer diagnosis, lung cancer treatment, and lung cancer disease management – this free online curriculum offers CME, CE, and CPE credit to oncologists and clinicians who care for patients with lung cancer. |
| The curriculum programs are updated continuously throughout the year. |
| The Advanced Certificate Program: Lung Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible. |
|
|
|
Features: |
- Outstanding faculty of noted oncology experts - co-chaired by
|
Roy S. Herbst, MD, PhD
Professor of Medicine
Department of Thoracic/Head
and Neck Medical Oncology
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas |
|
Corey J. Langer, MD, FACP
Medical Director
Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania |
- Timely and engaging information.
- Continuous program updates, news, and announcements
- E-mail notification as a course becomes available
- Lung cancer CME program offers CME credit, CE credit or CPE credit
- Certificate of advanced study in lung cancer awarded upon completion of all 24 course posttests and evaluations
|
Curriculum Overview:
|
Intensive 12-month curriculum explores both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
- NCCN Lung Cancer Treatment Guidelines
- Lung Cancer Risk Factors and Risk Assessment
- Screening and Early Detection of Lung Cancer
- Diagnosis and Lung Cancer Symptoms
- Lung Cancer Staging
| - | Using TNM classification of malignant tumors in NSCLC (stages IA, IB, IIA, IIB, IIIA, IIIB, IV [metastatic]; early, locally advanced and advanced tumors) |
| - | Using limited stage and extensive stages in SCLC |
- Current and emerging innovative lung cancer treatment options and strategies
| - |
Chemotherapy — including newer agents such as paclitaxel, pralatrexate, and talotrexin |
| - |
Chemoradiation |
| - |
Neoadjuvant and adjuvant chemotherapy |
| - |
Consolidative chemotherapy |
| - |
Targeted therapies: vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor (EGFR) inhibitors, matrix metalloprotease (MMP) inhibitors, farnesyl transferase (FT) inhibitors, multikinase inhibitors, inhibitors of Ras, HDAC, mTOR, Met, MEK, toll and p13K, that include the following drugs among others – gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, lonafarnib, vandetanib, cetuximab |
- Supportive care
|
Learning Objectives:
- Assess the diagnosis and staging of lung cancer utilizing knowledge of tumor node metastases classification, location of tumor, performance status, and surgical resectability in order to determine appropriate stage-specific treatment approaches.
- Apply evidence-based guidelines to formulate treatment strategies for patients with early- and late-stage lung cancer.
- Evaluate the appropriate use of chemotherapeutic agents in treatment strategies for lung cancer patients that improve outcomes through knowledge of their efficacy and safety.
- Integrate targeted therapies into more successful treatment regimens for lung cancer patients by assessing the efficacy and safety of these agents.
|
|
| Treatment Strategies Discussed |
- Chemotherapy - including paclitaxel, pralatrexate, & talotrexin
- Chemoradiation
- Neoadjuvant & adjuvant chemotherapy
- Consolidative chemotherapy
- Targeted therapies: gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, lonafarnib, vandetanib, cetuximab
|
| Covered Topics Include |
- NCCN Treatment Guidelines
- Risk Factors and Risk Assessment
- Screening and Early Detection
- Diagnosis
- Staging
- Using TNM classification of malignant tumors in NSCLC
- Using limited stage and extensive stages in SCLC
|
 |
Lung Cancer News powered by
 | |
|
|
About the Program
